Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Jérôme Contamine, Sanofi's CFO for nearly a decade, plans to step down later this year after a transition period.

Novo Nordisk has teamed up on a project that rewards diabetes patients with lower copays if they stick with their meds.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

Eli Lilly’s first oncology campaign launched last week, putting the drugmaker on a growing list of pharma companies running DTC ads for cancer drugs.

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

Amazon's plan to jump into drug sales has hit a snag, and the retail giant has reportedly put at least one plan on ice.